DUBLIN--(BUSINESS WIRE)-- <\/p>\n
Research and Markets has announced the addition of the \"Chinese Patent Medicine Industry Report, 2012-2015\" report to their offering. <\/p>\n
In recent years, China's Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Over the same period, the total profit maintained a CAGR of 26.6%, and the gross margin remained higher than the average level of the overall pharmaceutical industry. <\/p>\n
In succession to the Opinions on Promoting the Development of Traditional Chinese Medicine Services and Trade, the Twelfth Five-Year Plan on the Development of Traditional Chinese Medicine and other favorable policies, the new National Essential Drugs List published in March 2013 increased the number of Chinese patent medicine from 102 in 2009 to 203, and the proportion in total quantity from 33% to 39%. As a result, China's Chinese patent medicine market demand is expected to grow rapidly in the next five years. <\/p>\n
Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases, tumor diseases, respiratory system diseases, musculoskeletal diseases and digestive system diseases are top five categories of Chinese patent medicine for hospitals in China. The Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases occupies the largest market share, which remained at around 37% in 2006-2012. <\/p>\n
Key Topics Covered <\/p>\n
1. Overview of Chinese Patent Medicine <\/p>\n
1.1 Definition and Features <\/p>\n
1.2 Classification <\/p>\n
2. Operating Environment for Chinese Patent Medicine Industry <\/p>\n
<\/p>\n
Excerpt from: <\/p>\n
Research and Markets: Chinese Patent Medicine Industry Report, 2012-2015<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" DUBLIN--(BUSINESS WIRE)-- Research and Markets has announced the addition of the \"Chinese Patent Medicine Industry Report, 2012-2015\" report to their offering. In recent years, China's Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Over the same period, the total profit maintained a CAGR of 26.6%, and the gross margin remained higher than the average level of the overall pharmaceutical industry Continue reading